Skip to main content
Retour
AMLX logo

Amylyx Pharmaceuticals, Inc.

Qualité des données : 100%
AMLX
NASDAQ Healthcare Biotechnology
13,66 €
▲ 0,13 € (0,96%)
Cap. Boursière : 1,14B
Fourchette du Jour
13,20 € 13,70 €
Fourchette 52 Semaines
3,11 € 17,49 €
Volume
896 797
Moyenne 50J / 200J
14,34 € / 11,68 €
Clôture Précédente
13,53 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -7,9 0,4
P/B 3,7 2,9
ROE % -61,6 3,7
Net Margin % 3,9
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Objectif de Cours des Analystes

Hold
22,00 € +61.1%
Low: 19,00 € High: 28,00 €
BPA Prévisionnel
-1,35 €
CA Est.
81000

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 2,07 €
0,44 € – 3,76 €
540 M 2
FY2029 0,69 €
0,15 € – 1,26 €
320 M 4
FY2028 -0,57 €
-1,04 € – 0,23 €
150 M 6

Points Clés

Debt/Equity of 0,02 — conservative balance sheet
Negative free cash flow of -123,48M
PEG of 0,12 suggests growth is underpriced

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)-100,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-61,59%
ROIC-36,94%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
0,02
Current Ratio14,27
Interest Coverage0,00

Valorisation

P/E Ratio
-7,85
P/B Ratio3,72
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -100,00% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -144,74M
ROE -61,59% ROA -43,51%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -123,48M
ROIC -36,94% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,02 Current Ratio 14,27
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -7,85 P/B Ratio 3,72
P/S Ratio N/A PEG Ratio 0,12
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 1,14B Enterprise Value 914,79M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 87,37M 380,79M 22,23M 0,0
Net Income -144,74M -301,74M 49,27M -198,38M -87,93M
EPS (Diluted) -1,53 -4,43 0,70 -2,98 -1,52
Gross Profit -525 000,0 45,22M 355,35M 19,24M 0,0
Operating Income -153,29M -314,73M 38,80M -201,34M -82,69M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 332,65M 193,63M 517,45M 391,45M 105,61M
Total Liabilities 27,39M 28,87M 84,02M 50,85M 256,78M
Shareholders' Equity 305,26M 164,77M 433,43M 340,61M -151,17M
Total Debt 5,96M 1,98M 4,24M 6,28M 0,0
Cash & Equivalents 226,65M 77,39M 170,20M 62,53M 50,19M
Current Assets 323,67M 189,43M 464,67M 382,13M 104,95M
Current Liabilities 22,69M 28,41M 82,04M 46,61M 17,40M